TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of serious adverse events associated with the vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects reporting solicited systemic adverse events of severity (grade 3) or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects experiencing spontaneous adverse events of severity (grade 3) or higher and considered associated with the vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects reporting local reactogenicity of severity (grade 3) or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Development of Ventilator-Associated Pneumonia (VAP)
Endpoint domain: Adverse events/effects
Primary endpoint: EV-Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response rate to Dacomitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medication Adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Effectiveness of quetiapine XR treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of quetiapine XR treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ambulatory care visit rates for acute otitis media
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Carbon Dioxide Production (CO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minute ventilation (VE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of aerosol cyclosporine in treating COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in GAIN's Substance Frequency Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: User Acceptance of and Satisfaction With the SAM App
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Medication Changes That Are Adhered to
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteomic changes in Cutaneous T-cell lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of persistent hypertension defined by 24 hours BP measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of microalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Frequency of damage to the retina of the eyes (retinopathy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Respondents Reporting Any Drug Use
Endpoint domain: Adverse events/effects
Primary endpoint: Condomless Anal Sex With Casual Partners
Endpoint domain: Adverse events/effects
Primary endpoint: Drug Abuse Screening Test-10 Total Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Falls Incidence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment failure within the first year after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate according to RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Side effects as assessed by NCI CTC
Endpoint domain: Adverse events/effects
Primary endpoint: Release of incretins hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cortisol plasmatic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean changes in total Ashworth scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent Change in Incontinence Associated Dermatitis (IAD) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of contact persons developing anti-SARS-CoV-2 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of hyperandrogenism signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Safety and tolerability of CAR-CLDN18.2 T-cell therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 dose (RP2D) of CT041 therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of CT041 by Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants diagnosed with multiple sclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Success rate of arterial or femoral catheter placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: neoplasm diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intensity of anxiety in children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hunger and satiety sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Reduction From Baseline in Actinic Keratosis (AK) Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Delivery mode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Adequate response defined as no request for supplemental analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Beck Depression Inventory-Second Edition (BDI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Hearing Handicap Inventory for the Elderly (HHIE)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: granulosa cell apoptosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radioactivity parameters in plasma and whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification and report of cases of uveitis associated with drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Post-intervention physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Evoked Potential (VEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Lung Clearance Index (LCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Consolidation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complication due to the device
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of BRUE-type discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skin transepidermal water loss (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: absolute change in glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Depth of cuts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Closeness to blood vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum concentration of digoxin in plasma after single dose (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of digoxin in plasma over the time interval 0 to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in episodic memory neurocognitive test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modulation of PI3K/mTOR pathway readouts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Central retinal thickness (CRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete or Partial Immune Tolerance Induction (ITI) Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number and severity of Covid-19 infections
Endpoint domain: Adverse events/effects
Primary endpoint: Fatigue Scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Comfort Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Discomfort Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recurrence of angina at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects With Modified Rankin Scale (mRS) Score 0-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated single oral dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report of daily cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intentions to reduce leisure sitting time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intentions to reduce occupational sitting time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximal inspiratory pressures (MIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximal expiratory pressures (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: RBC transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of participants with viral remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with viral control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to viral detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success of resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to first occurrence of death or confirmed non-fatal myocardial infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Community Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events and serious adverse events meeting expedited adverse (EAE) criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Time to 99% Inhibition of Serum Thromboxane (TxB2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Completed Patient Quality of Life Surveys
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean percent change in fasting plasma triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-Traumatic Stress Disorder (PTSD) symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Proceed to Course V Within 2-6 Weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Progression Free Survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Post extubation stridor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Compliance to study treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bleeding within 24 hours after cvc application
Endpoint domain: Adverse events/effects
Primary endpoint: Other complications within the first 24 hours
Endpoint domain: Adverse events/effects
Primary endpoint: peripapillary RNFL thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fibrosis regression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of liver decompensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients with complete tumor removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Global Swallowing Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of acitretin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Overall Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PMS symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Urinary Albumin to Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence and intensity of adverse events graded according to CTCAE V4.03
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal voluntary activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal aortic diameter measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: TFPI activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of metastatic lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cmax (CC-90007)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ (CC-90007)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t (CC-90007)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (CC-90007)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference between esophageal temperature and nasopharyngeal temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Knowledge and Recommendations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient's Understanding of the Disease and Bleeding Signs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to the study protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Curve serum insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AUC 0-480 min serum FDKP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient observer scar assessment scale (POSAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in motor cortical map expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: stringent Complete Response (sCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: appropriateness of empirical antibiotics choosing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: appropriateness of de-escalation of therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Any sexually transmitted infection (STI)
Endpoint domain: Adverse events/effects
Primary endpoint: Neurological sensory assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Oesophageal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pleural pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation Timing at first session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation Timing at 3 months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Drug Liking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fat mass (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Free fat mass (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent decrease of fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Adverse Events, Dose Reductions and Withdrawals Due to Anemia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who died
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free survival (PFS) rate at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: RANKL level in GCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OPG level in GCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm Lymphedema Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical case presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients experiencing unacceptable toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Cytokine phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SARS-CoV-2 antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of deliveries without medical assistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Brain connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cardiac hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uterine Artery Doppler Mean Pulsatility Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Soluble FMS-like Tyrosine Kinase 1 (sFlt-1)/ Placental Growth Factor (PlGF) Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: time to full diet intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: post-operative stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in executive control function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in monitoring frequency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time until discontinuation of IV vasopressors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-contamination rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting a Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Frequency of Logins
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Scapular muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper Limb Functional Performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of Post thrombotic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Ataxia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Validity of the ability of the measure to objectify the memory deficit in dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CERAD-TS1 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum tolerated dose (MTD) of ruxolitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelial function (EndoPAT Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Age of death
Endpoint domain: Mortality/survival
Primary endpoint: Overall Response to CVT Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with changes in electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global tolerability assessment by the investigator on a verbal rating scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Radiation dose to the testicles, scrotal skin, and penile shaft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma B-carotene levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Percent Change in Lumbar Spine Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of occurrence of a cognitive disorder
Endpoint domain: Mortality/survival
Primary endpoint: Compliance with inhaled corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Force expiratory volume in one second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Magnetization transfer ratio histogram parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes